Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Gastroenterol. 2013 Jul;29(4):446-53. doi: 10.1097/MOG.0b013e3283622848.

Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus.

Author information

1
Department of Medicine, Division of Gastroenterology and Hepatology, Dallas VA Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas 75216, USA. Kerry.Dunbar@utsouthwestern.edu

Abstract

PURPOSE OF REVIEW:

Endoscopic eradication therapy is frequently used to treat dysplasia and early cancers in Barrett's esophagus. This review addresses some of the recent developments in the field of endoscopic eradication therapy for Barrett's esophagus.

RECENT FINDINGS:

Data on the effectiveness of Barrett's esophagus ablation programs have been published recently, with excellent results for dysplasia eradication. Studies describing long-term results have shed light on the durability of endoscopic ablation, with recurrence of Barrett's esophagus and neoplasia seen in some cases, particularly at the gastroesophageal junction. Risk factors for failed ablation include longer Barrett's esophagus segments and persistent gastroesophageal reflux. New developments include studies combining radiofrequency ablation (RFA) and endoscopic mucosal resection into a single endoscopic session, endoscopic submucosal dissection for Barrett's esophagus neoplasia, and a simplified RFA algorithm. New data on the cost-effectiveness of RFA have also been published, suggesting that RFA is cost-effective for both high-grade and low-grade dysplasia, but not for nondysplastic Barrett's esophagus. A systematic review has shown that lymph node metastases are rare (∼2%) with intramucosal adenocarcinoma, supporting the use of endoscopic eradication for that lesion.

SUMMARY:

Research and clinical experience with the endoscopic therapies for Barrett's esophagus continue to grow. Proper patient selection and technique are critical for ensuring a good outcome. Endoscopic surveillance after any of the ablative therapies still appears to be necessary.

PMID:
23703368
DOI:
10.1097/MOG.0b013e3283622848
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center